H. Lundbeck (CPSE:HLUN B) Has Fresh News, But What Is Drawing Attention Now?
The trigger for H. Lundbeck (CPSE:HLUN B) today is fresh THRIVE data on eptinezumab in migraine patients who had not responded well to a previous CGRP preventive, a clinically important treatment gap.
Set against a DKK43.68 share price, Lundbeck’s 90-day share price return of 1.53% and modest 1.58% year-to-date gain suggest only gentle momentum, while the 23.31% three-year total shareholder return points to a stronger longer run for patient holders.
Compare Lundbeck’s THRIVE momentum in neurology with other hand-picked healthcare and biotech opportunities by using the 615 high quality undiscovered gems for ideas that may still be under the radar.
Lundbeck now has fresher clinical support for eptinezumab, yet only modest recent share price gains. Does that mix still skew the risk reward toward buyers, or has most of the upside already been priced in?
Most Popular Narrative: 10% Undervalued
Against the DKK43.68 close, the most followed narrative for H. Lundbeck points to a fair value of DKK48.73, suggesting investors are not fully paying for its broader neuroscience opportunity yet.
A maturing pipeline with 5 to 6 mid
to late-stage assets (bexicaserin, amlenetug, D1/D2 agonist) targeting high unmet needs in CNS and neuro-rare diseases, underpins prospects for portfolio diversification and long-term growth, likely driving both revenue and gross margin expansion as late-stage candidates move towards approval.
See why 15 investors see H. Lundbeck as 10% undervalued.
Result: Fair Value of DKK48.73 (UNDERVALUED)
Still, H. Lundbeck’s heavy reliance on a few blockbuster drugs and rising generic pressure on older brands could quickly challenge that 10% undervalued narrative.
Find out about the key risks to this H. Lundbeck narrative.
Next Steps
If the mix of fresh trial support and valuation debate around H. Lundbeck leaves you undecided, move quickly and assess both sides of the story. To see the balance of concerns and potential upsides flagged by investors, review the 3 key rewards and 1 important warning sign.
Looking for more H. Lundbeck investment ideas?
Do not stop with H. Lundbeck. Use the Simply Wall Street Screener to surface fresh opportunities that fit your style before other investors focus on them.
- Target potential mispricing and hunt for quality businesses trading below their estimated worth through the 192 high quality undervalued stocks.
- Lock in potential income ideas by scanning resilient payers with the 168 dividend fortresses.
- Prioritise resilience first by using the 227 resilient stocks with low risk scores to filter for companies with steadier risk profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com